Certain cancers, immune system diseases, blood diseases, and sickle cell disease require bone marrow ablation/transplantation (BMA/T). The standard protocol for BMA/T consists of high dose chemotherapy and/or Total Body Irradiation (TBI). This standard treatment is physically devastating to patients, especially younger and older patients.
Radiopharmaceuticals are potentially the best option because there may be fewer patient side effects. Many radiopharmaceuticals have excellent safety records. However, current products have long half-lives and high levels of impurities, meaning patients could be immunocompromised for unacceptably long periods of time.
CycloSam® may be able to become the new standard of care. The short half-life (46 hours) and low impurity profile means a patient may be able to be treated and transplanted a few days later.